公开(公告)号：US20220133712A1

公开(公告)日：2022-05-05

申请号：US17573693

申请日：2022-01-12

Applicant: NeOnc Technologies, Inc.

Inventor： Thomas CHEN ,  Daniel LEVIN ,  Satish PUPPALI

IPC: A61K31/495 ,  A61K31/415 ,  A61K47/54 ,  A61K45/06 ,  A61N5/10 ,  C07D207/26 ,  C07D231/12 ,  C07D487/04 ,  A61K31/4188 ,  A61K31/045 ,  A61K31/4015 ,  C07B59/00 ,  C07C33/14 ,  A61K9/00

Abstract: The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

公开(公告)号：US11147809B2

公开(公告)日：2021-10-19

申请号：US16313388

申请日：2017-06-30

Applicant: NeOnc Technologies, Inc.

Inventor： Thomas Chen

IPC: A61K31/495 ,  C07D231/12 ,  A61K31/4188 ,  A61K47/54 ,  C07B59/00 ,  A61K31/4015 ,  A61K9/00 ,  A61K31/045 ,  A61K31/415 ,  C07D207/26 ,  C07C33/14 ,  C07D487/04 ,  A61K45/06 ,  A61N5/10 ,  A61K31/635 ,  A61K47/55 ,  A61K31/366

Abstract: The present methods treat neurofibromatosis by a administering to a subject perillyl alcohol or iso-perillyl alcohol. The present methods also treat neurofibromatosis by administering to a subject a carbamate of perillyl alcohol, or a carbamate of iso-perillyl alcohol. The perillyl alcohol carbamate may comprise perillyl alcohol conjugated with rolipram or temozolomide.

公开(公告)号：US20210130271A1

公开(公告)日：2021-05-06

申请号：US17123365

申请日：2020-12-16

Applicant: NEONC Technologies, Inc.

Inventor： Thomas CHEN ,  Daniel LEVIN ,  Satish PUPPALI

IPC: C07C29/92 ,  A61K31/045 ,  C07C201/16 ,  C07C201/12 ,  C07C67/14 ,  C07C29/88 ,  C07C29/86 ,  A61K31/4188 ,  A61K45/06 ,  A61N5/10 ,  C07C29/78

Abstract: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

公开(公告)号：US10899691B2

公开(公告)日：2021-01-26

申请号：US16575587

申请日：2019-09-19

Applicant: NEONC Technologies, Inc.

Inventor： Thomas Chen ,  Daniel Levin ,  Satish Puppalli

IPC: C07C29/92 ,  C07C67/14 ,  C07C201/12 ,  A61K31/045 ,  C07C29/78 ,  C07C29/88 ,  C07C201/16 ,  A61K31/4188 ,  A61K45/06 ,  A61N5/10 ,  C07C29/86

Abstract: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

公开(公告)号：US20200230132A1

公开(公告)日：2020-07-23

申请号：US16722816

申请日：2019-12-20

Applicant: NeOnc Technologies, Inc.

Inventor： Thomas CHEN

IPC: A61K31/495 ,  A61K47/55 ,  A61K47/54

Abstract: A method for treating brain metastases of a cancer in a mammal includes administering to the mammal a therapeutically effective amount of a perillyl alcohol carbamate, such as TMZ-POH. The brain metastases can be originated or spread from breast cancer. The penllyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent, such as a chemotherapeutic agent. The chemotherapeutic agents that may be used in the present invention include a DNA alkylating agent, a topoisomerase inhibitor, an endoplasmic reticulum stress inducing agent, a platinum compound, an antimetabolite, an enzyme inhibitor, and a receptor antagonist.

公开(公告)号：US10696680B2

公开(公告)日：2020-06-30

申请号：US16126586

申请日：2018-09-10

Applicant: NeOnc Technologies, Inc.

Inventor： Thomas Chen ,  Daniel Levin ,  Satish Puppali

IPC: C07D487/04 ,  A61P35/00 ,  C07D231/12

Abstract: A pharmaceutical composition is provided which includes perillyl alcohol conjugated with a therapeutic agent and further includes and a hydrolyzable acylated aliphatic tail. A method of using the pharmaceutical composition is also provided for treating a condition or disease of a patient, e.g., cancer.

公开(公告)号：US20200170961A1

公开(公告)日：2020-06-04

申请号：US16675605

申请日：2019-11-06

Applicant: NeOnc Technologies, Inc.

Inventor： Thomas Chen ,  Daniel Levin ,  Satish Pupalli ,  Daniel Anthony Dickman

IPC: A61K31/045 ,  A61K47/54 ,  A61K47/55 ,  A61N5/10 ,  A61K31/4015 ,  A61K31/4188 ,  A61K31/415 ,  A61K31/325 ,  A61K31/165 ,  A61K45/06 ,  A61K31/05 ,  C07D207/26 ,  C07D487/04 ,  C07D231/12 ,  C07C271/22

Abstract: The present invention provides for a method of treating a disease such as cancer, comprising the step of administering to a patient a therapeutically effective amount of an isomer or analog of monoterpene or sesquiterpene (or its derivative), such as an isoperillyl alcohol. The present invention also provides for a method of treating a disease comprising the step of administering to a patient a therapeutically effective amount of a derivative of an isomer or analog of monoterpene or sesquiterpene, such as an isoperillyl alcohol carbamate. The derivative may be an isoperillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The route of administration may vary, including inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

公开(公告)号：US20190241568A1

公开(公告)日：2019-08-08

申请号：US16126586

申请日：2018-09-10

Applicant: NeOnc Technologies, Inc.

Inventor： Thomas CHEN ,  Daniel LEVIN ,  Satish Puppali

IPC: C07D487/04 ,  A61P35/00 ,  C07D231/12

Abstract: A pharmaceutical composition is provided which includes perillyl alcohol conjugated with a therapeutic agent and further includes and a hydrolyzable acylated aliphatic tail. A method of using the pharmaceutical composition is also provided for treating a condition or disease of a patient, e.g., cancer.

公开(公告)号：US20190054082A1

公开(公告)日：2019-02-21

申请号：US15916549

申请日：2018-03-09

Applicant: NeOnc Technologies, Inc.

Inventor： Thomas CHEN

IPC: A61K31/495 ,  A61K47/55 ,  A61K47/54

Abstract: A method for treating brain metastases of a cancer in a mammal includes administering to the mammal a therapeutically effective amount of a perillyl alcohol carbamate, such as TMZ-POH. The brain metastases can be originated or spread from breast cancer.

公开(公告)号：US09913838B2

公开(公告)日：2018-03-13

申请号：US15026649

申请日：2014-10-08

Applicant: NEONC TECHNOLOGIES INC.

Inventor： Thomas Chen

IPC: A61K31/495 ,  A61K47/54 ,  A61K47/55 ,  A61K9/00

CPC classification number: A61K31/495 ,  A61K9/0043 ,  A61K9/0085 ,  A61K47/54 ,  A61K47/55

Abstract: A method for treating brain metastases of a cancer in a mammal includes administering to the mammal a therapeutically effective amount of a perillyl alcohol carbamate, such as TMZ-POH. The brain metastases can be originated or spread from breast cancer. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent, such as a chemotherapeutic agent. The chemotherapeutic agents that may be used in the present invention include a DNA alkylating agent, a topoisomerase inhibitor, an endoplasmic reticulum stress inducing agent, a platinum compound, an antimetabolite, an enzyme inhibitor, and a receptor antagonist.